Related Experiment Video
Updated: Jun 19, 2026
Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
Published on: July 30, 2018
Recombinant adenovirus encoding vasohibin prevents tumor angiogenesis and inhibits tumor growth
Dajiang Li1, Kun Zhou, Shuguang Wang
1Institute of Hepatobiliary Surgery, Southwest Hospital, Chongqing, China.
Abstract:
Numerous lines of evidence have shown that angiogenesis plays a pivotal role in the development of tumors. Therefore anti-angiogenesis therapy represents a potentially promising approach to cancer therapy. Recently, a new inhibitor called vasohibin was discovered to operate as an intrinsic and highly specific feedback inhibitor in the process of angiogenesis. However, to date, reports on the antitumor and anti-angiogenic properties of vasohibin have been very limited. To explore the potential of vasohibin as an anti-angiogenesis therapeutic, we constructed a recombinant adenovirus encoding vasohibin. Our data showed that the recombinant adenovirus encoding vasohibin could prevent tumor angiogenesis and tumor growth. Notably, angiogenesis in the tumors was prevented without any apparent side-effects. Therefore, the findings suggested that the recombinant adenovirus encoding vasohibin might be valuable as a potential strategy for antitumor angiogenesis therapy in the clinic.
Insights
This study shows that a new therapy using recombinant adenovirus encoding vasohibin effectively prevents tumor angiogenesis and growth. This approach offers a promising strategy for cancer treatment with no apparent side effects.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Angiogenesis is crucial for tumor development, making anti-angiogenesis therapy a promising cancer treatment strategy.
- Vasohibin is a newly discovered, highly specific inhibitor of angiogenesis.
- Limited data exists on vasohibin's antitumor and anti-angiogenic potential.
Purpose of the Study:
- To explore the potential of vasohibin as an anti-angiogenesis therapeutic agent.
- To construct a recombinant adenovirus encoding vasohibin for therapeutic evaluation.
Main Methods:
- Construction of a recombinant adenovirus carrying the vasohibin gene.
- In vivo evaluation of the adenovirus's effect on tumor angiogenesis and growth.
Main Results:
- The recombinant adenovirus encoding vasohibin successfully prevented tumor angiogenesis.
- Tumor growth was significantly inhibited by the vasohibin-encoding adenovirus.
- No apparent side effects were observed during the treatment.
Conclusions:
- Recombinant adenovirus encoding vasohibin demonstrates significant antitumor and anti-angiogenic properties.
- This approach shows potential as a novel clinical strategy for combating cancer by targeting angiogenesis.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:10Mechanism of Angiogenesis
01:27Tumor Immunotherapy